It was reported that ibrutinib-resistant MCL cell lines demonstrated genetic lesions leading to aberrant activation of the alternative NFκB pathway, namely activation of mitogen-activated protein kinase 14 (MAP3K14)/NFκB-inducing kinase (NIK). The gene discussed is MAP3K14; the disease is mantle cell lymphoma.